How much of Sun Pharma Advanced Research Company Limited (NSE: SPARC) do insiders own?

0


If you want to know who actually controls Sun Pharma Advanced Research Company Limited (NSE: SPARC), then you will need to look at the makeup of its share register. Large companies usually have institutions as shareholders, and we usually see insiders holding shares in smaller companies. Warren Buffett said he enjoys “a business with sustainable competitive advantages, led by skilled people and owner-centered.” So it’s nice to see some insider ownership as it may suggest that the management is owner-driven.

Sun Pharma Advanced Research is a smaller company with a market cap of 37 billion yen, so it may still go under the radar of many institutional investors. Looking at our data on ownership groups (below), it appears that institutions are visible on the share register. We can zoom in on the different ownership groups, to find out more about Sun Pharma Advanced Research.

Check out our latest review for Sun Pharma Advanced Research

Distribution of NSEI property: SPARC April 2, 2021

What does Institutional Ownership tell us about Sun Pharma’s advanced research?

Institutional investors generally compare their own returns to the returns of a commonly tracked index. They therefore generally consider buying larger companies that are included in the relevant benchmark.

As you can see, institutional investors own a large share of Sun Pharma Advanced Research. This suggests some credibility among professional investors. But we cannot rely on this fact alone because institutions sometimes make bad investments, like everyone else. If several institutions change their mind about a stock at the same time, you could see the stock price drop quickly. So it’s worth checking out Sun Pharma Advanced Research’s profit history below. Of course, the future is what really matters.

profit and revenue growth
NSEI: SPARC Profits and Revenue Growth April 2, 2021

Hedge funds don’t have a lot of shares in Sun Pharma Advanced Research. Looking at our data we can see that the largest shareholder is Shanghvi Finance Pvt Ltd with 52% of the shares outstanding. With such a huge stake in the property, we infer that they have significant control over the future of the business. With respectively 11% and 3.9% of shares outstanding, Dilip Shanghvi and Sun Pharmaceutical Industries Ltd., Employee Benefit Trust are the second and third largest shareholders. Dilip Shanghvi, who is the second shareholder, also holds the title of Top Key Executive.

Institutional ownership research is a good way to assess and filter the expected performance of a stock. The same can be achieved by studying the feelings of analysts. Our information suggests there is no analyst coverage of the stock, so it is likely little known.

Sun Pharma Advanced Research Insider Property

The definition of company insiders can be subjective and vary from jurisdiction to jurisdiction. Our data reflects individual insiders, capturing at least board members. The management ultimately reports to the board of directors. However, it is not uncommon for managers to be board members, especially if they are founders or CEOs.

I generally consider insider ownership to be a good thing. However, there are times when it is more difficult for other shareholders to hold the board accountable for decisions.

It appears that insiders own a significant proportion of Sun Pharma Advanced Research Company Limited. Insiders have a 5.9 billion yen stake in the 37 billion yen venture. It’s great to see insiders so invested in the business. It might be worth checking out if these insiders have bought recently.

General public property

With a 20% stake, the general public has some influence over Sun Pharma Advanced Research. While this property size may not be enough to influence a policy decision in their favor, they can still have a collective impact on company policies.

Owned by a private company

We can see that the private companies own 57% of the issued shares. It is difficult to draw conclusions from this fact alone, so it is worth considering who owns these private companies. Sometimes insiders or other related parties have an interest in shares of a public company through a separate private company.

Next steps:

While it is worth considering the different groups that own a business, there are other factors that are even more important. Be aware that Sun Pharma’s advanced search shows 4 warning signs in our investment analysis , and 3 of them are potentially serious …

Sure, you might find a fantastic investment looking elsewhere. So take a look at this free list of interesting companies.

NB: The figures in this article are calculated from data for the last twelve months, which refer to the 12-month period ending on the last day of the month of date of the financial statement. This may not be consistent with the figures in the annual report for the entire year.

If you decide to trade Sun Pharma Advanced Research, use the cheapest platform * which is ranked # 1 overall by Barron’s, Interactive brokers. Trade stocks, options, futures, currencies, bonds and funds in 135 markets, all from one integrated account. Promoted

This Simply Wall St article is general in nature. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative material. Simply Wall St has no position in any of the stocks mentioned.
*Interactive Brokers Ranked Least Expensive Broker By StockBrokers.com Online Annual Review 2020

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at) simplywallst.com.


Share.

Leave A Reply